Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.
Chronic Lymphocytic Leukemia
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia|
- LPL Protein Expression [ Time Frame: 1 year ] [ Designated as safety issue: No ]Determine the degree of LPL protein expression in CLL cells using a novel LPL antibody, correlate with IgHV mutation status, and compare this association with other prognostic markers
- Fatty acid acquisition and synthesis [ Time Frame: 1 year ] [ Designated as safety issue: No ]Demonstrate that CLL cells also possess the enzymatic machinery for fatty acid acquisition and synthesis as shown by the expression of LPL, CD36, SDC1, and fatty acid synthase
Biospecimen Retention: Samples With DNA
10 cc of peripheral blood and Archived lymph node tissue or bone marrow samples
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
No intervention. Each patient will have blood drawn at a standard of care venipuncture.
The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL expression correlates with a more aggressive type of CLL. The investigators propose that LPL protein expression on CLL cells is prognostic and that LPL and other proteins involved in fatty acid metabolism are critical for CLL cells to survive.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01460238
|Contact: Frederick Lansigan, MD||800-639-6918||Cancer.Research.Nurse@Dartmouth.edu|
|United States, New Hampshire|
|Dartmouth-Hitchcock Medical Center||Recruiting|
|Lebanon, New Hampshire, United States, 03756|
|Contact: Frederick Lansigan, MD 800-639-6918 Cancer.Research.Nurse@Dartmouth.edu|
|Principal Investigator: Frederick Lansigan, MD|
|Principal Investigator:||Frederick Lansigan, MD||Dartmouth-Hitchcock Medical Center|